Dernières nouvelles pour Merus (NASDAQ:MRUS) Stock

Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV

<a href="https://www.globenewswire.com/Tracker?data=NCrzNoU8yG3rqGkuad5oez3SzNsyzo2BctG8WH-FtL0Cds5D7DndYCzk5K4CaTbYNejhAylgOrnJYMb4e1eW1A==">Merus N.V</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics&#xAE; and Triclonics&#xAE;) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics&#xAE;&nbsp;targeting EGFR and LGR5.&nbsp;
The phase 2, open-label trial will evaluate the safety and antitumor activity of petosemtamab&nbsp;monotherapy in 3L+ mCRC, post anti-EGFR therapy. To be eligible for enrollment, patients must lack certain mutations as detected in plasma by ctDNA NGS, including KRAS, NRAS.

Biotech

News

General

MRUS

Merus announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer

Citigroup analyst Yigal Nochomovitz maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $89 to $97.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Merus, Raises Price Target to $97

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $85 price target.

Reiteration

Needham Reiterates Buy on Merus, Maintains $85 Price Target

<ul>
<li>Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025</li>
<li>Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025</li>
</ul>

Reported Saturday, Merus Unveils Clinically Meaningful Activity For Petosemtamab In 2L+ R/M HNSCC And Expands Evaluation In mCRC

On Wednesday, the FDA approved Merus N.V.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) Bizengri&nbsp;(zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42328116/merus-announces-fda-approval-of-bizengri-zenocutuzumab-zbco-for-nrg1-pancreatic-adenocarcinoma-and" rel="noreferrer noopener">prior systemic therapy</a>.
Bizengri is Merus&#8217;s first approved medicine and is based on the proprietary&nbsp;Biclonics technology platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42272645/merus-licenses-us-commercialization-rights-for-cancer-potential-zenocutuzumab-analyst-highlight-merus-pipeline" rel="noreferrer noopener">Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus&#8217; Pipeline</a>
These indications are approved under accelerated approval based on the overall response rate (ORR) and duration of response (DOR).
Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Bizengri&nbsp;20 mg/mL Injection for Intravenous Use is expected to be available to patients in the coming weeks.
Bizengri&#8217;s approval&nbsp;is based on data from the eNRGy trial. In patients with&nbsp;NRG1+ pancreatic adenocarcinoma (n=30), Bizengri&nbsp;demonstrated an ORR of 40%.
DOR in&nbsp;NRG1+ pancreatic adenocarcinoma ranged from 3.7 months to 16.6 months. In the same trial, patients with&nbsp;NRG1+ NSCLC (n=64) treated with Bizengri&nbsp;demonstrated an ORR of 33%. The median DOR in&nbsp;NRG1+ NSCLC was 7.4 months.
b writes, &#8220;Investor focus remains on petosemtamab, with the next key catalyst for the company being updated data for petosemtamab in previously treated head and neck squamous cell carcinoma (HNSCC) at ESMO Asia on December 7.&#8221;
The analyst assumes Bizengri will be priced at roughly $30,000 per treatment and estimates combined peak U.S. sales in NRG1 fusion NSCLC and PDAC attributable to Merus (based on an estimated 8% royalty rate) of roughly $16.5 million.
Price Action: MRUS stock is down 3.70% at $43.80 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42324351/fda-approved-sickle-cell-therapies-from-bluebird-bio-and-vertex-join-medicaid-innovation-program" target="_blank" rel="noreferrer noopener">FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program</a></li>
</ul>

Analyst Color

Health Care

Trading Ideas

Merus Scores Its First FDA Approval For Lung Cancer Drug

Guggenheim analyst Michael Schmidt maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $93 to $111.

Guggenheim Maintains Buy on Merus, Raises Price Target to $111

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) is still &#8220;very,<a href="https://www.benzinga.com/quote/mrus/earnings"> very speculative.&#8221;</a>
On Wednesday, Merus announced the FDA approval of BIZENGRI for NRG1+ pancreatic adenocarcinoma and NRG1+ non–small cell lung cancer based on safety and efficacy data from the eNRGy study.
&#8220;Storied company, terrific. It does great,&#8221; Cramer said when asked about Allison Transmission Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>). &#8220;I actually would prefer you to swap out right now and go to be with Mary Barra at GM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>). Cheaper and will be just as good.&#8221;
On Oct.29, Allison Transmission reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.
NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) has &#8220;no earnings,&#8221; Cramer said. &#8220;I want you to take out almost all of your cost basis and let the rest run.&#8221;
On Dec. 4, the company earlier announced a Memorandum of Understanding (MOU) with the U.S. Department of Energy's Idaho Operations Office to explore siting, construction and operation of its proprietary ‘ZEUS&#8217; and ‘ODIN&#8217; microreactors at the <a href="https://www.benzinga.com/news/24/12/42323743/whats-going-on-with-nano-nuclear-energy-nne-stock">Idaho National Laboratory (INL).</a>
&#8220;It is living off, I think, a lot of the federal money that's been spent. So, I don't want to get greedy,&#8221; Cramer said when asked about Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>). He recommended taking some off the table and let the rest run.
On Nov. 6, Sterling Infrastructure reported worse-than-expected third-quarter revenue results and lowered the top end of its FY24 revenue guidance.
Price Action:
<ul>
<li>Allison Transmission shares gained 0.9% to settle at $117.95 on Wednesday.</li>
<li>Nano Nuclear Energy shares fell 0.5% to close at $26.50.</li>
<li>Sterling Infrastructure shares gained 1.7% to close at $198.82 on Wednesday.</li>
<li>Merus shares fell 1.6% to settle at $45.49 during the session.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42313903/top-3-tech-and-telecom-stocks-that-may-implode-this-quarter">Top 3 Tech And Telecom Stocks That May Implode This Quarter</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

ALSN

STRL

Jim Cramer: This Health Care Stock Is 'Very, Very Speculative'

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $85 price target.

HC Wainwright & Co. Reiterates Buy on Merus, Maintains $85 Price Target

<ul>
<li>BIZENGRI&#xAE; is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1</li>
<li>Merus and Partner Therapeutics announced a license agreement for U.S. commercialization</li>
</ul>
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ex5f2gygbCiuJdH_pXLq4WKCDbHu1pHyh3pZ1HZo_2uFBcbeJdnK5mE1HgnqqSDsuIwevPpmuqgNxIgdlI4XaQ==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics&#xAE;&nbsp;and Triclonics&#xAE;), announced today that the U.S. Food and Drug Administration (FDA) approved BIZENGRI&#xAE; (zenocutuzumab-zbco), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. These indications are approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BIZENGRI&#xAE; has a Boxed WARNING for Embryo-Fetal Toxicity and warnings for infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions, interstitial lung disease (ILD)/pneumonitis, and left ventricular dysfunction.1 See Important Safety Information below.
We believe this approval fills an important need for patients with NRG1+ cancer who have not previously had treatment options approved to specifically target this driver. BIZENGRI&#xAE; (zenocutuzumab-zbco) 20 mg/mL Injection for Intravenous Use is expected to be available to patients in the coming weeks.

Merus Announces FDA Approval Of BIZENGRI For NRG1+ Pancreatic Adenocarcinoma And NRG1+ Non–Small Cell Lung Cancer Based On Safety And Efficacy Data From The eNRGy Study

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelera[…]al-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic</a>

FDA Grants Accelerated Approval To Zenocutuzumab-zbco For Non-Small Cell Lung Cancer And Pancreatic Adenocarcinoma

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $111 to $109.

Guggenheim Reiterates Buy on Merus, Lowers Price Target to $109

Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) and Partner Therapeutics Inc, a private biotechnology company focused on hematology and oncology, entered into an agreement in which Merus has exclusively licensed to Partner Therapeutics the right to commercialize zenocutuzumab (Zeno) for NRG1 fusion-positive (NRG1+) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42264173/merus-and-partner-therapeutics-announce-license-agreement-for-the-u-s-commercialization-of-zenocut" rel="noreferrer noopener">cancer in the U.S.</a>
Under the terms of the agreement, following a specified transition period, Partner Therapeutics will assume full rights to U.S. commercialization of Zeno for the treatment of NRG1+ cancer.
In exchange for the rights granted under the license agreement, Merus will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments based on Zeno&#8217;s annual net sales in NRG1+ cancer in the U.S. for any potential future sales.
The FDA is currently reviewing a biologics license application for Zeno for patients with previously treated NRG1+ non-small cell lung and pancreatic cancer.
Last month, the FDA extended the Prescription Drug User Fee Act (PDUFA) goal date for the zenocutuzumab Biologics License Application, which is currently <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41739987/merus-receives-fda-extension-of-pdufa-for-zenocutuzumab" rel="noreferrer noopener">under priority review</a>.
The FDA has extended the PDUFA goal date to February 4, 2025, to enable sufficient time to review information recently submitted by the Company in response to a CMC information request. No additional clinical data have been requested.
William Blair is positive on Zeno but writes that Merus&#8217;s core thesis and primary value driver continue to be centered on petosemtamab.
On Sunday, Merus announced the publication of an abstract regarding petosemtamab in previously treated patients with recurrent/metastatic head and neck squamous cell carcinoma on the European Society for Medical Oncology <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42256976/merus-announces-publication-of-an-abstract-on-petosemtamab-as-2l-treatment-of-rm-hnscc-at-the-esmo" rel="noreferrer noopener">Asia Congress website</a>.
The abstract presents updated clinical data on petosemtamab from the initial expansion cohort (1500 mg) and a new dose-comparison cohort (1100 mg vs. 1500 mg).
The analyst writes that in the near term, updated data for petosemtamab monotherapy will be a key catalyst for Merus shares.
&#8220;We believe the company's Multiclonics platform produces molecules with attractive drug-like properties, providing continued pipeline expansion and additional business development opportunities&#8230;, with potential to be a market leader in the multi blockbuster head and neck cancer treatment landscape,&#8221; the analyst writes.
Price Action: MRUS stock is up 9.50% at $49.10 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42270592/pharma-pushes-to-revise-medicare-drug-price-negotiation-law-under-trump-administration" target="_blank" rel="noreferrer noopener">Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump</a></li>
</ul>
Photo via Shutterstock.

Equities

Movers

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline

U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Monday.
Shares of XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) rose sharply <a href="https://www.benzinga.com/24/12/42260165/li-auto-xpeng-nio-heres-how-november-deliveries-of-chinese-ev-startups-stack-up">during Monday's session</a>.
The company delivered 30,895 vehicles last month, marking an increase of 54% year-over-year and 29% from October.
The Guangzhou-based EV startup said that the company&#8217;s deliveries of the XPeng Mona M03 hatchback coupe alone exceeded 10,000 units for the third consecutive month since launch. Deliveries of the XPeng P7+ sedan, which the company launched last month, also exceeded 7,000 units.
XPeng shares jumped 6.4% to $12.82 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) shares gained 29.9% to $26.04 after the company announced its Phase 3 PANOVA-Trial met its primary endpoint and demonstrated a statistically significant improvement in its median overall survival rate.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) surged 22% to $39.83 after the company announced it completed a review by an independent special committee and stated EY&#8217;s conclusions were not supported by findings.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) jumped 17% to $9.92.</li>
<li>Nebius Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>) shares gained 15.5% to $25.40 after the company announced it entered a $700 million private placement financing agreement with institutional investors.</li>
<li>Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) gained 15.1% to $10.65.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) jumped 14.6% to $24.41.</li>
<li>PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) surged 14.3% to $50.15 after the company announced it signed a global licensee and collaboration agreement with Novartis for its PTC518 Huntington&#8217;s Disease program.</li>
<li>Dana Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) gained 14% to $11.39 after Barclays upgraded the stock from Equal-Weight to Overweight and raised its price target from $12 to $18.</li>
<li>MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) gained 12.9% to $22.60. The company, on Friday, posted first-quarter results.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) climbed 11.3% to $7.87.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) rose 8.8% to $0.9000.</li>
<li>Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) gained 8.2% to $161.94.</li>
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) gained 8% to $48.43 after the company announced it entered into an agreement to exclusively license the right to Ptx the right to commercialize Zenocutuzumab (Zeno) for Nrg1 Fusion-positive cancer in the US.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) rose 5.7% to $25.63 after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $28 to $30.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42264122/wall-streets-most-accurate-analysts-give-their-take-on-3-financial-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields</a></li>
</ul>

Intraday Update

ENVX

FSLY

MNSO

NBIS

NVCR

PTCT

RXRX

SMCI

XPEV

ZETA

XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday

WIIM

Merus shares are trading higher after the company announced it entered into an agreement to exclusively license the right to Ptx the right to commercialize Zenocutuzumab (Zeno) for Nrg1 Fusion-positive cancer in the US.

Under the terms of the agreement, following a specified transition period, PTx will assume full rights to U.S. commercialization of Zeno for the treatment of NRG1+ cancer. In exchange for the rights granted under the license agreement, Merus will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments based on the annual net sales of Zeno in NRG1+ cancer in the U.S. for any potential future sales.

Contracts

Merus And Partner Therapeutics Have Entered Into An Agreement In Which Merus Has Exclusively Licensed To Ptx The Right To Commercialize Zenocutuzumab (Zeno) For Nrg1 Fusion-positive Cancer In US

<a href="https://www.globenewswire.com/Tracker?data=0jqx6oiQK6OAEHWWr0opEkjg0sad2-iIQznMZgyFDuY8X608nFoptscWDTobgewhmWZMR423_Z0oola8H2nm4A==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics&#xAE; and Triclonics&#xAE;), today announced the publication of an abstract regarding petosemtamab, a Biclonics&#xAE; targeting EGFR and LGR5, in previously treated (2L+) patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) on the European Society for Medical Oncology (ESMO&#xAE;) Asia Congress website. The abstract presents updated clinical data on petosemtamab from the initial expansion cohort (1500 mg) and a new dose-comparison cohort (1100 mg vs. 1500 mg) in 2L+ HNSCC for presentation at the ESMO&#xAE; Asia Congress 2024 taking place in Singapore, Dec. 6-8, 2024.

Events

Merus Earlier Announced Publication On Abstract On Petosemtamab As 2L+ Treatment Of R/M HNSCC At ESMO Asia Congress 2024;  Said Petosemtamab 1500 Mg Monotherapy Phase 2 Interim Data Continues To Demonstrate Clinically Meaningful Activity In 2L+ HNSCC

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587635585064ed0001400105/michael-blum">Wells Fargo analyst Michael Blum </a>initiated coverage on GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with an Overweight rating and announced a price target of $385. GE Vernova shares closed at $342.77 on Wednesday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer analyst Michael Phillips initiated coverage on International General Insurance Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGIC#NASDAQ">IGIC</a>) with an Outperform rating and announced a price target of $30. Intl General Insurance shares closed at $24.54 on Wednesday. <a href="https://www.benzinga.com/quote/IGIC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel analyst Lars Kjellberg initiated coverage on Mativ Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATV#NYSE">MATV</a>) with a Hold rating and announced a price target of $15.5. Mativ shares closed at $12.52 on Wednesday. <a href="https://www.benzinga.com/quote/MATV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Richard Law initiated coverage on Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy rating and announced a price target of $73. Merus shares closed at $42.93 on Wednesday. <a href="https://www.benzinga.com/quote/MRUS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst A.J. Rice initiated coverage on The Ensign Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Buy rating and announced a price target of $175. Ensign Group shares closed at $144.66 on Wednesday. <a href="https://www.benzinga.com/quote/ENSG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21132522/image-224-1024x578.png" alt="" class="wp-image-659530" style="width:710px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21132522/image-224-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21132522/image-224-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21132522/image-224-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21132522/image-224.png 1190w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42114009/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields</a></li>
</ul>

Initiation

ENSG

IGIC

MATV

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analyst Ami Fadia of Needham maintained a Buy rating on Merus (MRUS – Research Report), retaining the price target of $85.00. Ami Fadia has given h...

Merus's Promising Prospects: Buy Rating Highlighted by Positive Data on Peto's Efficacy in HNSCC

In a report released today, Asthika Goonewardene from Truist Financial reiterated a Buy rating on Merus (MRUS – Research Report). The company's sha...

Truist Financial Sticks to Its Buy Rating for Merus (MRUS)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merus (MRUS – Research Report), Arcellx Inc (ACLX – ...

Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Arcellx Inc (ACLX)

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Merus (MRUS – Research Report) today and set a price target of $96.00. The compan...

Stifel Nicolaus Sticks to Their Buy Rating for Merus (MRUS)

Citi raised the firm's price target on Merus (MRUS) to $97 from $89 and keeps a Buy rating on the shares after petosemtamab monotherapy data in sec...

Merus price target raised to $97 from $89 at Citi

Leerink Partners analyst Andrew Berens has maintained their bullish stance on MRUS stock, giving a Buy rating yesterday. Andrew Berens has given hi...

Merus Positioned for Growth Amid Promising Clinical Data and Resilience to Market Fluctuations

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of $73.0...

Promising Potential of Merus's Petosemtamab in HNSCC: A Buy Recommendation

Merus (MRUS) announced that the first patient has been dosed in the company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreat...

Merus doses first patient in petosemtamab trial

Harbor Health Care ETF Q3 2024 Commentary

Canaccord Genuity analyst John Newman reiterated a Buy rating on Merus (MRUS – Research Report) today and set a price target of $67.00. The company...

Canaccord Genuity Sticks to Its Buy Rating for Merus (MRUS)

ACHC

ACLX

ASND

DXCM

ICLR

LEGN

MEDI

NBIX

Press Releases

Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine's RNA Platform

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

Earnings

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

Merus Receives FDA extension of PDUFA for zenocutuzumab

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Comments

Merus

Actualités

Dernières nouvelles pour Merus (NASDAQ:MRUS) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL